{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:58:42Z","timestamp":1783537122867,"version":"3.55.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"F Hoffmann-La Roche Ltd","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-vascular endothelial growth factor therapy has revolutionised the treatment of neovascular age-related macular degeneration (nAMD). However, some patients face recurrent and persistent disease activity despite ongoing treatment. Faricimab (trade name: Vabysmo) is a recently approved therapy which targets two pathways involved in nAMD. This study aims to assess changes in best-corrected visual acuity (BCVA) and treatment frequency among patients currently treated for nAMD who switch to intravitreal faricimab therapy under a treat-and-extend regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The FURGGHORN Study is a prospective, open-label, single-arm, multicentre investigator-initiated clinical trial. 102 patients with nAMD meeting inclusion criteria were recruited from 12 clinical sites across Australia and Singapore. Following 4\u2009monthly loading doses of faricimab, treatment intervals were adjusted according to a regimen developed based on real-world practice patterns and consensus guidelines. The primary endpoint is the change from BCVA at week 52. Secondary endpoints include the proportions of patients at different treatment intervals, changes in central macular thickness and retinal fluid dimensions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was designed, implemented and reported in accordance with the International Conference on Harmonisation Harmonised Tripartite Guidelines for Good Clinical Practice, with applicable local regulations and with the ethical principles laid down in the Declaration of Helsinki. Ethics approval was obtained from Bellberry Limited (2022-12-1388), St Vincent\u2019s Hospital Human Research Ethics Committee (2023\/STE01568) and Singhealth Centralized Institutional Review Board (2023-2190). Results will be disseminated at scientific meetings and through peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12623000215628.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002326","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:55:11Z","timestamp":1761029711000},"page":"e002326","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-084X","authenticated-orcid":false,"given":"Long T","family":"Phan","sequence":"first","affiliation":[{"name":"Cureos Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hong","sequence":"additional","affiliation":[{"name":"Cureos Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Chang","sequence":"additional","affiliation":[{"name":"Eastwood Eye Specialists, Eastwood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[{"name":"Strathfield Retina Clinic, Strathfield, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[{"name":"The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia"},{"name":"Lane Cove Eye Surgery, Lane Cove, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemmy C M","family":"Cheung","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore"},{"name":"Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-4513","authenticated-orcid":false,"given":"Geoffrey K","family":"Broadhead","sequence":"additional","affiliation":[{"name":"Cureos Research, Sydney, New South Wales, Australia"},{"name":"The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1585","authenticated-orcid":false,"given":"Andrew A","family":"Chang","sequence":"additional","affiliation":[{"name":"The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia"},{"name":"Sydney Retina, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2026010721204937000_10.1.e002326.1","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026010721204937000_10.1.e002326.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64525-7"},{"key":"2026010721204937000_10.1.e002326.3","first-page":"527","article-title":"Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy","volume":"6","author":"Cheung","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026010721204937000_10.1.e002326.4","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12463"},{"key":"2026010721204937000_10.1.e002326.5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","article-title":"Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"34","author":"Chandra","year":"2020","journal-title":"Eye (Lond)"},{"key":"2026010721204937000_10.1.e002326.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"2026010721204937000_10.1.e002326.7","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S185052"},{"key":"2026010721204937000_10.1.e002326.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.06.002"},{"key":"2026010721204937000_10.1.e002326.9","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10442"},{"key":"2026010721204937000_10.1.e002326.10","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003003"},{"key":"2026010721204937000_10.1.e002326.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"2026010721204937000_10.1.e002326.12","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721204937000_10.1.e002326.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"2026010721204937000_10.1.e002326.14","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"},{"key":"2026010721204937000_10.1.e002326.15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721204937000_10.1.e002326.16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721204937000_10.1.e002326.17","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424315"},{"key":"2026010721204937000_10.1.e002326.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration","volume":"13","author":"Tamiya","year":"2023","journal-title":"Sci Rep"},{"key":"2026010721204937000_10.1.e002326.19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"key":"2026010721204937000_10.1.e002326.20","unstructured":"Reynolds R , Peto T , Bailey CC , et al . Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with diabetic macular edema (DME) in the UK: FARWIDE-DME. Invest Ophthalmol Vis Sci 2024;65."},{"key":"2026010721204937000_10.1.e002326.21","unstructured":"Tabano D , Ko S , Borkar D , et al . Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINA-AMD study. Invest Ophthalmol Vis Sci 2024;65."},{"key":"2026010721204937000_10.1.e002326.22","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2023","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"2026010721204937000_10.1.e002326.23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","volume":"11","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"2026010721204937000_10.1.e002326.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.11.025"},{"key":"2026010721204937000_10.1.e002326.25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol","year":"2021","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:35Z","timestamp":1767849695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjophth-2025-002326"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002326","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}